WASHINGTON, D.C. (July 31, 2015) —The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Rajesh Ranganathan, Ph.D. will join the organization as Vice President of Science and Regulatory Advocacy effective August 3, 2015.
“Rajesh’s experience in academia, the biopharmaceutical industry and government will be invaluable as he leads PhRMA’s ongoing efforts to promote innovation and enhanced efficiency in drug discovery and development,” stated Bill Chin, M.D., Executive Vice President of Science and Regulatory Advocacy.
A trained geneticist and neurobiologist, Dr. Ranganathan was previously the Director of the Office of Translational Research at the National Institute for Neurological Disorders and Stroke (NINDS) where he led the organization’s efforts to more quickly and effectively convert basic and translational research results into new therapies. He assumed that role after serving as the senior advisor to the Director of the National Institutes of Health (NIH) in the area of translational medicine.
Prior to his time at the NIH, Dr. Ranganathan spent seven years at the Novartis Institutes for BioMedical Research (NIBR) as a director in the scientific strategy and portfolio management group. He also founded and led the Global Office of Scientific Education for NIBR.
“I am honored to join the team at PhRMA and contribute to their work with the many stakeholders in the biomedical ecosystem to advance drug discovery and development, regulatory sciences and productive collaborations,” said Dr. Ranganathan.
Dr. Ranganathan is a graduate of Amherst College. He holds a Ph.D. degree in biology from the Massachusetts Institute of Technology and conducted his postdoctoral training at Harvard Medical School and the Fred Hutchinson Cancer Research Center.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.